Trevena Inc (TRVN.OQ)
1.73USD
4:00pm EDT
$-0.02 (-1.14%)
$1.75
$1.75
$1.75
$1.72
91,121
190,752
$3.63
$1.35
About
Overall
| Beta: | -0.52 |
| Market Cap(Mil.): | $117.17 |
| Shares Outstanding(Mil.): | 66.95 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| TRVN.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 185.16 | 33.25 |
| EPS (TTM): | -1.22 | -- | -- |
| ROI: | -97.70 | -0.71 | 13.13 |
| ROE: | -126.95 | -2.76 | 14.96 |
BRIEF-Trevena Says Chief Financial Officer Roberto Cuca Will Resign, Effective May 3, 2018
* TREVENA SAYS ON APRIL 9, ROBERTO CUCA, CHIEF FINANCIAL OFFICER OF CO FORMALLY NOTIFIED CO OF HIS RESIGNATION, EFFECTIVE AS OF MAY 3, 2018 - SEC FILING Source text: (https://bit.ly/2GVszsP) Further company coverage:
BRIEF-Trevena Reports Q4 Loss Per Share $0.24
* COMPANY EXPECTS THAT EXPENSES WILL DECREASE IN 2018 COMPARED TO 2017
BRIEF-Trevena Inc Says FDA Indicated To Co That PDUFA Date For Olinvo NDA Is Nov 2
* TREVENA INC - ON JAN 5, FDA INDICATED TO THE CO THAT PDUFA REVIEW DATE FOR OLINVO NDA IS NOV 2
BRIEF-Trevena Announces FDA Acceptance For Review Of New Drug Application For OLINVO(Oliceridine) Injection
* TREVENA ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR OLINVO (OLICERIDINE) INJECTION
BRIEF-Trevena Inc says Q3 loss per share $0.27
* Trevena reports third quarter 2017 financial results and announces new positive clinical trial data
BRIEF-Trevena announces submission of NDA to U.S. FDA for Olinvo
* Trevena announces submission of new drug application to U.S. FDA for Olinvo (oliceridine injection)
BRIEF-trevena announces publication and presentations of olinvo clinical data
* Trevena announces publication and presentations of olinvo (oliceridine injection) clinical data Source text for Eikon: Further company coverage:
Estimates